바이러스 벡터 제조 서비스 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global viral vector manufacturing services market size is expected to reach USD 40.88 Billion in 2034 from USD 8.76 Billion in 2025, growing at a CAGR of 18.67 during 2026-2034.This market is witnessing rapid growth due to the increasing demand for gene therapies and advanced biologics. Viral vectors are essential tools used in the delivery of genetic material for therapeutic purposes. The rising prevalence of genetic disorders and the growing focus on personalized medicine are driving market growth. Pharmaceutical and biotechnology companies are increasingly outsourcing manufacturing services to specialized providers to meet the growing demand for viral vectors.

Growth drivers include advancements in biotechnology and the increasing number of clinical trials for gene therapies. The need for scalable and cost-effective manufacturing solutions is encouraging the adoption of specialized services. Regulatory support for innovative therapies and the approval of new gene-based treatments are also contributing to market expansion. Additionally, the growing investment in research and development is accelerating the development of viral vector technologies.

Looking ahead, the viral vector manufacturing services market is expected to witness significant advancements in production technologies and capacity expansion. Companies are likely to focus on improving efficiency and reducing costs to meet increasing demand. The development of next-generation vectors with enhanced safety and efficacy will further drive market growth. As gene therapy continues to evolve, the demand for reliable and scalable manufacturing services is anticipated to rise.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Viral Vectors
• Plasmid DNA

By Product & Services

• Product
• Services

By Workflow

• Upstream Manufacturing
• Downstream Manufacturing

By Application

• Cell and Gene Therapy
• Vaccine Development
• Research

By Disease Indication

• Cancer
• Generic Disorders
• Infectious Diseases
• Others

By End User

• Pharmaceutical and Biopharmaceutical Companies
• Academics and Research Institutes
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific Inc., Lonza Group AG, WuXi AppTec Co. Ltd., Merck KGaA, GenScript Biotech Corporation, FUJIFILM Holdings Corporation, Catalent Inc., Charles River Laboratories International Inc., Novartis International AG, Sartorius AG, Danaher Corporation, Oxford Biomedica plc, Precision Biosciences Inc., Bluebird Bio Inc., VGXI Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL VECTOR MANUFACTURING SERVICES MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Plasmid DNA Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL VECTOR MANUFACTURING SERVICES MARKET: BY PRODUCT & SERVICES 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product & Services
• 5.2. Product Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL VECTOR MANUFACTURING SERVICES MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Workflow
• 6.2. Upstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Downstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL VECTOR MANUFACTURING SERVICES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Cell and Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Vaccine Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL VIRAL VECTOR MANUFACTURING SERVICES MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Disease Indication
• 8.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Generic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL VIRAL VECTOR MANUFACTURING SERVICES MARKET: BY END USER 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End User
• 9.2. Pharmaceutical and Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Academics and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL VIRAL VECTOR MANUFACTURING SERVICES MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Type
  • 10.2.2 By Product & Services
  • 10.2.3 By Workflow
  • 10.2.4 By Application
  • 10.2.5 By Disease Indication
  • 10.2.6 By End User
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Type
  • 10.3.2 By Product & Services
  • 10.3.3 By Workflow
  • 10.3.4 By Application
  • 10.3.5 By Disease Indication
  • 10.3.6 By End User
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Type
  • 10.4.2 By Product & Services
  • 10.4.3 By Workflow
  • 10.4.4 By Application
  • 10.4.5 By Disease Indication
  • 10.4.6 By End User
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Type
  • 10.5.2 By Product & Services
  • 10.5.3 By Workflow
  • 10.5.4 By Application
  • 10.5.5 By Disease Indication
  • 10.5.6 By End User
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Type
  • 10.6.2 By Product & Services
  • 10.6.3 By Workflow
  • 10.6.4 By Application
  • 10.6.5 By Disease Indication
  • 10.6.6 By End User
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL VIRAL VECTOR MANUFACTURING SERVICES INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Thermo Fisher Scientific Inc
  • 12.2.2 Lonza Group AG
  • 12.2.3 WuXi AppTec Co. Ltd
  • 12.2.4 Merck KGaA
  • 12.2.5 GenScript Biotech Corporation
  • 12.2.6 FUJIFILM Holdings Corporation
  • 12.2.7 Catalent Inc
  • 12.2.8 Charles River Laboratories International Inc
  • 12.2.9 Novartis International AG
  • 12.2.10 Sartorius AG
  • 12.2.11 Danaher Corporation
  • 12.2.12 Oxford Biomedica Plc
  • 12.2.13 Precision Biosciences Inc
  • 12.2.14 Bluebird Bio Inc
  • 12.2.15 VGXI Inc